Page 19 - GPD-2-2
P. 19

Gene & Protein in Disease                                                              MOR in cancer



            Writing – review & editing: Ruidong Ding, Yiming Zhao,   Carcinogenesis, 31(1): 27–36.
               Dingyuan Su, Yue Zhang, Jia-Yi Wang, Shuangyu Lv,      https://doi.org/10.1093/carcin/bgp220
               Xinying Ji
                                                               10.  Baeriswyl V, Christofori G, 2009, The angiogenic switch in
            Ethics approval and consent to participate            carcinogenesis. Semin Cancer Biol, 19(5): 329–337.
            Not applicable.                                       https://doi.org/10.1016/j.semcancer.2009.05.003
                                                               11.  Bergers G, Benjamin LE, 2003, Tumorigenesis and the
            Consent for publication                               angiogenic switch. Nat Rev Cancer, 3(6): 401–410.
            All authors consent to the publication of this manuscript.     https://doi.org/10.1038/nrc1093

            Availability of data                               12.  Robert J, 2013, Biology of cancer metastasis. Bull Cancer,
                                                                  100(4): 333–342.
            Data availability are not applicable to this review article.     https://doi.org/10.1684/bdc.2013.1724

            References                                         13.  Suhail Y, Cain MP, Vanaja K, et al., 2019, Systems biology of
                                                                  cancer metastasis. Cell Syst, 9(2): 109–127.
            1.   Sung H, Ferlay J, Siegel RL,  et al., 2021, Global cancer
               statistics 2020: GLOBOCAN estimates of incidence and      https://doi.org/10.1016/j.cels.2019.07.003
               mortality worldwide for 36 cancers in 185 countries.  CA   14.  Fidler IJ, 2003, The pathogenesis of cancer metastasis: The
               Cancer J Clin, 71(3): 209–249.                     ‘seed and soil’ hypothesis revisited.  Nat Rev Cancer, 3(6):
               https://doi.org/10.3322/caac.21660                 453–458.
            2.   Bray F, Laversanne M, Weiderpass E,  et al., 2021, The      https://doi.org/10.1038/nrc1098
               ever-increasing importance of cancer as a leading cause of   15.  Lambert AW, Pattabiraman DR, Weinberg RA, 2017,
               premature death worldwide. Cancer, 127(6): 3029–30.  Emerging biological principles of metastasis.  Cell, 168(4):
               https://doi.org/10.1002/cncr.33587                 670–691.
            3.   Xia C, Dong X, Li H, et al., 2022, Cancer statistics in China      https://doi.org/10.1016/j.cell.2016.11.037
               and United States, 2022: Profiles, trends, and determinants.   16.  Massague J, Obenauf AC, 2016, Metastatic colonization by
               Chin Med J (Engl), 135(5): 584–590.                circulating tumour cells. Nature, 529(7586): 298–306.
               https://doi.org/10.1097/CM9.0000000000002108       https://doi.org/10.1038/nature17038
            4.   Avella Patino DM, Radhakrishnan V, Suvilesh KN,  et al.,   17.  Li Y, Li F, Jiang F,  et al., 2016, A mini-review for cancer
               2022, Epigenetic regulation of cancer immune cells. Semin   immunotherapy: Molecular understanding of PD-1/PD-L1
               Cancer Biol, 83: 377–383.                          pathway & translational blockade of immune checkpoints.
               https://doi.org/10.1016/j.semcancer.2021.06.022    Int J Mol Sci, 17(7): 1151.
            5.   Chen C, Man N, Liu F,  et al., 2022, Epigenetic and      https://doi.org/10.3390/ijms17071151
               transcriptional regulation of innate immunity in cancer.   18.  Zhang H, Zhou D, Gu J, et al., 2021, Targeting the mu-opioid
               Cancer Res, 82(11): 2047–2056.                     receptor for cancer treatment. Curr Oncol Rep, 23(10): 111.
               https://doi.org/10.1158/0008-5472.CAN-21-3503       https://doi.org/10.1007/s11912-021-01107-w
            6.   Berdasco M, Esteller M, 2010, Aberrant epigenetic landscape   19.  Ramirez MF, Gorur A, Cata JP, 2021, Opioids and cancer
               in cancer: How cellular identity goes awry. Dev Cell, 19(5):   prognosis: A  summary of the clinical evidence.  Neurosci
               698–711.                                           Lett, 746: 135661.
               https://doi.org/10.1016/j.devcel.2010.10.005       https://doi.org/10.1016/j.neulet.2021.135661
            7.   Torry DS, Cooper GM, 1991, Proto-oncogenes in   20.  Trescot  AM, Datta S,  Lee M, et al., 2008,  Opioid
               development and cancer. Am J Reprod Immunol, 25(3):   pharmacology. Pain Physician, 11(2 Suppl): S133–S153.
               129–132.
                                                               21.  Spetea M, Schmidhammer H, 2020, Opioids and their
               https://doi.org/10.1111/j.1600-0897.1991.tb01080.x  receptors: Present and emerging concepts in opioid drug
                                                                  discovery. Molecules, 25(23): 5658.
            8.   Spandidos DA, Anderson ML, 1989, Oncogenes and onco-
               suppressor genes: Their involvement in cancer.  J  Pathol,      https://doi.org/10.3390/molecules25235658
               157(1): 1–10.
                                                               22.  Ballantyne JC, 2006, Opioids for chronic nonterminal pain.
               https://doi.org/10.1002/path.1711570102            South Med J, 99(11): 1245–1255.
            9.   Sharma S, Kelly TK, Jones PA, 2010, Epigenetics in cancer.      https://doi.org/10.1097/01.smj.0000223946.19256.17

            Volume 2 Issue 2 (2023)                         13                        https://doi.org/10.36922/gpd.282
   14   15   16   17   18   19   20   21   22   23   24